(PO16-70-22) Probiotic Supplementation in Very Low Birthweight Infants: Effects on Systemic Immunity and Intestinal Inflammation

The ePoster content is available to NUTRITION 2022 LIVE ONLINE attendees who are logged in.<br><br>If you are registered, log in and then come back here to use this button.

Presenting Author(s)

Elizabeth A. Reznikov, DO, PhD
– Medicine/Pediatrics Resident, MedStar Georgetown University Hospital, Washington, District of Columbia, United States

Co-Author(s)

MP

Michael K. Pippa, MD
– MedStar Georgetown University Hospital
JP

Jennifer M. Pak, MD
– MedStar Georgetown University Hospital
RR

Raymond K. Riley, BSN, RNC-NIC
– MedStar Georgetown University Hospital
PP

Pinaki Panigrahi, MD, PhD
– Georgetown University Medical Center
Lewis P. Rubin, MD
– Professor, Georgetown University Medical Center, N.W., Washington D.C., District of Columbia, United States

Disclosure(s):

Elizabeth A. Reznikov, DO, PhD: No relevant financial relationship(s) with ineligible companies to disclose.

Lewis P. Rubin, MD: Abbott Nutrition: Advisory Committee/Board Member (Ongoing); Grant/Research Support (Ongoing)

Objectives: To investigate serum immune/inflammatory profiles in preterm very low birthweight (BW) infants enrolled in a randomized trial of daily supplementation with a multi-strain probiotic. A central hypothesis is probiotics will promote T cell homeostasis via a T regulatory cell (Treg) response and suppress inflammatory Th1/Th17 cytokine profiles to promote intestinal microbiota diversity, reduce inflammation, and support barrier function.

Methods: After parental informed consent, preterm infants admitted to a neonatal ICU are randomized into 2 groups (+/- probiotics; 30/group by NNT) stratified by BW. The probiotic group receives daily Tri-Blend (Abbott; B. lactis [BB-12], B. infantis [BB-02], S. thermophilis [H-4]; 0.5 g, 10⁸CFU/g) from early feeding to 34 weeks post-menstrual age. Data include: diagnoses, interventions, medications, feedings, growth trajectories, and length of stay; intestinal integrity protein biomarkers; fecal DNA analysis for intestinal microbiomics using amplicon-based 16S rRNA gene sequencing and shotgun metagenomics; and fecal metabolomics. This presentation focuses on results from bimonthly serum cytokine, chemokine, and growth factor profiles assayed using customized multiplex magnetic bead antibody panels (Luminex).

Results: Longitudinal serum immune/immunomodulatory profiles (up to 7 samples/subject) and clinical data are available for 17 subjects (as of 02/2022). We measured 18 inflammatory/immunomodulatory small proteins; all analytes varied within recognized ranges for human serum/plasma and, consequently, are interpretable for analysis of systemic pro-/anti-inflammatory polarization and for products released by circulating T cell and macrophage subsets. Data indicate chronic heightened inflammation in these preterm infants and evolving profiles of Th1, Th2, Th17, and Treg-dependent cytokines/chemokines.

Conclusions: This is the first study that comprehensively profiles circulating immune system/inflammatory biomarkers in young infants. We demonstrate novel findings on multiple, longitudinally sampled biomarkers and characterize chronic inflammation in this population. Small subject numbers to date preclude conclusions on immunomodulatory effects of probiotics.

Funding Sources: Abbott Nutrition, Tano Research Fund, Georgetown University Medical Center